Cargando…

[(18)F]AlF-NOTA-FAPI-04 PET/CT uptake in metastatic lesions on PET/CT imaging might distinguish different pathological types of lung cancer

PURPOSE: Heterogeneity is found in the tumor microenvironment among different pathological types of tumors. Radionuclide-labeled fibroblast-activation-protein inhibitor (FAPI), as an important tracer for non-invasive imaging of the tumor microenvironment, can be used to evaluate the expression of FA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Yuchun, Cheng, Kai, Fu, Zheng, Zheng, Jinsong, Mu, Zhengshuai, Zhao, Chenglong, Liu, Xiaoli, Wang, Shijie, Yu, Jinming, Yuan, Shuanghu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940861/ https://www.ncbi.nlm.nih.gov/pubmed/34870727 http://dx.doi.org/10.1007/s00259-021-05638-z

Ejemplares similares

Diagnostic Value of (18)F-NOTA-FAPI PET/CT in a Rat Model of Radiation-Induced Lung Damage
por: Qin, Xueting, et al.
Publicado: (2022)

Visualization of Activated Fibroblasts in Heart Failure with Preserved Ejection Fraction with [(18)F]AlF-NOTA-FAPI-04 PET/CT Imaging
por: Sun, Fangfang, et al.
Publicado: (2023)

FAPI-04 PET/CT Using [(18)F]AlF Labeling Strategy: Automatic Synthesis, Quality Control, and In Vivo Assessment in Patient
por: Jiang, Xiao, et al.
Publicado: (2021)

[(18)F] AlF‑NOTA‑FAPI‑04 PET/CT as a promising tool for imaging fibroblast activation protein in gastrointestinal system cancers: a prospective investigation of comparative analysis with (18)F-FDG
por: Yang, Liping, et al.
Publicado: (2023)

Evaluation of (18)F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with (68)Ga-DOTATATE PET/CT
por: Hou, Jiale, et al.
Publicado: (2021)

Prospective comparison of [(18)F]AlF-NOTA-octreotide PET/MRI to [(68)Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
por: Boeckxstaens, Lennert, et al.
Publicado: (2023)

(68)Ga-FAPI-04 Versus (18)F-FDG PET/CT in the Detection of Hepatocellular Carcinoma
por: Wang, Hao, et al.
Publicado: (2021)

FAPI-04 Uptake in Healthy Tissues of Cancer Patients in (68)Ga-FAPI-04 PET/CT Imaging
por: Gündoğan, Cihan, et al.
Publicado: (2021)

Clinical application of Al(18)F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to (18)F-FDG
por: Lyu, Zhehao, et al.
Publicado: (2023)

Diagnostic value of [(68)Ga]Ga-FAPI-04 in patients with colorectal cancer in comparison with [(18)F]F-FDG PET/CT
por: Lin, Xinfeng, et al.
Publicado: (2023)

Preparation, Optimisation, and In Vitro Evaluation of [(18)F]AlF-NOTA-Pamidronic Acid for Bone Imaging PET
por: Hassan, Hishar, et al.
Publicado: (2022)

Prospective comparison of (68)Ga-FAPI-04 and (18)F-FDG PET/CT for tumor staging in nasopharyngeal carcinoma
por: Ding, Haoyuan, et al.
Publicado: (2022)

Dynamic PET/CT Imaging of (68)Ga-FAPI-04 in Chinese Subjects
por: Wang, Shuailiang, et al.
Publicado: (2021)

(68)Ga-FAPI-04 PET/CT Findings in Patients with Liver Cirrhosis
por: Tatar, Gamze, et al.
Publicado: (2023)

[(68)Ga]Ga-FAPI-04 PET MRI/CT in the evaluation of gastric carcinomas compared with [(18)F]-FDG PET MRI/CT: a meta-analysis
por: Wang, Yawen, et al.
Publicado: (2023)

Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience
por: Elboga, Umut, et al.
Publicado: (2022)

(68)Ga- or (18)F-FAPI PET/CT—what it can and cannot
por: Mori, Yuriko, et al.
Publicado: (2023)

Preparation and Evaluation of [(18)F]AlF-NOTA-NOC for PET Imaging of Neuroendocrine Tumors: Comparison to [(68)Ga]Ga-DOTA/NOTA-NOC
por: Dam, Johan Hygum, et al.
Publicado: (2022)

FAPI-74 PET/CT Using Either (18)F-AlF or Cold-Kit (68)Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
por: Giesel, Frederik L., et al.
Publicado: (2021)

Utility of [(68)Ga]FAPI-04 and [(18)F]FDG dual-tracer PET/CT in the initial evaluation of gastric cancer
por: Miao, Ying, et al.
Publicado: (2022)

(18)F-FAPI-04 PET/CT parameters predict PD-L1 expression in esophageal squamous cell carcinoma
por: Zhao, Yaqing, et al.
Publicado: (2023)

Preclinical evaluation and pilot clinical study of [(18)F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts
por: Hu, Kongzhen, et al.
Publicado: (2022)

Comparison of Diagnostic Efficacy of [(68)Ga]Ga-FAPI-04 and [(18)F]FDG PET/CT for Staging and Restaging of Gastric Cancer
por: Zhang, Shumao, et al.
Publicado: (2022)

[(18)F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[(18)F]FDG PET/CT
por: Mu, Xingyu, et al.
Publicado: (2022)

Head-to-head comparison of (68)Ga-FAPI-04 PET/CT and (18)F-FDG PET/CT in the evaluation of primary digestive system cancer: a systematic review and meta-analysis
por: Ouyang, Jiqi, et al.
Publicado: (2023)

The feasibility of (18)F-AlF-NOTA-PRGD2 PET/CT for monitoring early response of Endostar antiangiogenic therapy in human nasopharyngeal carcinoma xenograft model compared with (18)F-FDG
por: Cui, Yanfen, et al.
Publicado: (2016)

FAPI PET/CT Imaging—An Updated Review
por: Chandekar, Kunal Ramesh, et al.
Publicado: (2023)

Development of a Novel PET Tracer [(18)F]AlF-NOTA-C6 Targeting MMP2 for Tumor Imaging
por: Liu, Qinghua, et al.
Publicado: (2015)

[(18)F]AlF-NOTA-ADH-1: A new PET molecular radiotracer for imaging of N-cadherin-positive tumors
por: Liu, Zhenfeng, et al.
Publicado: (2023)

Head-to-Head Comparison of [(68) Ga]Ga-FAPI-46-PET/CT and [(18)F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer
por: Wegen, Simone, et al.
Publicado: (2022)

First Clinical Experience With [(68)Ga]Ga-FAPI-46-PET/CT Versus [(18)F]F-FDG PET/CT for Nodal Staging in Cervical Cancer
por: Wegen, Simone, et al.
Publicado: (2023)

Head-to-head comparison of [(68)Ga]Ga-FAPI-04 and [(18)F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma
por: Kuten, Jonathan, et al.
Publicado: (2021)

Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma
por: Gu, Bingxin, et al.
Publicado: (2022)

Comparison of (18)F-FDG PET/CT and (68)Ga-FAPI in Spindle Cell Rhabdomyosarcoma
por: Shen, Zhihui, et al.
Publicado: (2023)

Automated GMP compliant production of [(18)F]AlF-NOTA-octreotide
por: Tshibangu, Térence, et al.
Publicado: (2020)

(68)Ga-FAPI-04 PET/MR is helpful in differential diagnosis of pancreatitis from pancreatic malignancy compared to (18)F-FDG PET/CT: a case report
por: Shou, Yi, et al.
Publicado: (2021)

Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [(18)F]F-FDG PET/CT in Patients with Liver Malignancies
por: Siripongsatian, Dheeratama, et al.
Publicado: (2022)

Tumor angiogenesis at baseline identified by (18)F-Alfatide II PET/CT may predict survival among patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
por: Wei, Yuchun, et al.
Publicado: (2022)

A Comparative Study of Noninvasive Hypoxia Imaging with (18)F-Fluoroerythronitroimidazole and (18)F-Fluoromisonidazole PET/CT in Patients with Lung Cancer
por: Wei, Yuchun, et al.
Publicado: (2016)

FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors
por: Yang, Tianshuo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i85d4uoqmi9sttnjlj9tihiirh